Comparison of the vasoconstrictor effects of rizatriptan and sumatriptan in human isolated cranial arteries: immunohistological demonstration of the involvement of 5‐HT1B‐receptors
- 1 December 1998
- journal article
- research article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 46 (6) , 577-582
- https://doi.org/10.1046/j.1365-2125.1998.00821.x
Abstract
Aims We compared the vasoconstrictor effects of 5-HT with those of the selective 5-HT1B/1D-receptor agonists sumatriptan and rizatriptan in human isolated cranial (middle meningeal) arteries. In addition selective 5-HT1B- or 5-HT1D-receptor antibodies were used in combination with semiquantitative immunohistochemical techniques to compare the levels of expression of these receptors in human middle meningeal and coronary arteries. Methods Middle meningeal and coronary arteries were obtained (with consent) from either neurosurgical patients or donor hearts, respectively. Segments of middle meningeal artery were mounted in organ baths for isometric recording and cumulative concentration-effect curves to 5-HT, rizatriptan and sumatriptan were obtained. Frozen fresh sections of middle meningeal and coronary arteries were subjected to standard immunohistochemical techniques using specific 5-HT1B- or 5-HT1D-receptor primary antibodies and a radiolabelled secondary antibody. Data were subjected to analysis of variance (anova ) and nonlinear regression analysis. Results 5-HT, rizatriptan and sumatriptan were potent vasoconstrictors in human isolated middle meningeal artery (EC50 values=32, 90 and 71 nm, respectively). A significantly higher level of 5-HT1B-receptor immunoreactivity was detected in middle meningeal artery compared with coronary artery (anova, F=7.95, DF=1,4, P Conclusions Rizatriptan and sumatriptan act selectively to cause vasoconstriction in human isolated middle meningeal artery and are 10-fold more potent than in human coronary artery. The higher level of expression of 5-HT1B-receptors in middle meningeal compared with coronary artery provides a pharmacological basis for the craniovascular selectively of both rizatriptan and sumatriptan.Keywords
This publication has 21 references indexed in Scilit:
- Vasoconstriction in human isolated middle meningeal arteries: determining the contribution of 5‐HT1B‐ and 5‐HT1F‐receptor activationBritish Journal of Clinical Pharmacology, 1999
- Differential Distribution of 5Ht1D-and 5HT1B-Immunoreactivity within the Human Trigemino-Cerebrovascular System: Implications for the Discovery of New Antimigraine DrugsCephalalgia, 1997
- Initial human experience with MK-462 (rizatriptan): a novel 5=HTIDagonistPublished by Wiley ,1997
- Initial human experience with MK-462 (rizatriptan): a novel 5=HTIDagonistBritish Journal of Clinical Pharmacology, 1997
- Alignment of receptor nomenclature with the human genome: classification of 5-HT1B and 5-HT1D receptor subtypesTrends in Pharmacological Sciences, 1996
- Expression of serotonin receptor mRNAs in blood vesselsFEBS Letters, 1995
- Human arterial constrictor serotonin receptorsCardiovascular Research, 1993
- Coronary vasospasm induced by subcutaneous sumatriptan.BMJ, 1992
- Mode of action of the anti-migraine drug sumatriptanTrends in Pharmacological Sciences, 1991
- Migraine pain associated with middle cerebral artery dilatation: reversal by sumatriptanThe Lancet, 1991